FDA cancer policy office
This article was originally published in The Gray Sheet
Executive Summary
Review of therapeutic biologics and drugs for oncology imaging will be consolidated by a new office within FDA's Center for Drug Evaluation & Research. The Office of Oncology Drug Products will engage in policy development, provide technical consultation to FDA's device center, and serve as a point of contact for cancer professional organizations, the National Cancer Institute and stakeholders, FDA announces July 16. Recruitment of a director will begin this summer; the reorganization wrap-up is slated for the first half of 2005...